Olema Pharmaceuticals, Inc. 8-K

What Happened
Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K on June 23, 2026 reporting the results of its June 17, 2026 annual meeting of stockholders. Stockholders elected four Class III directors — Sean Bohen, M.D., Ph.D.; Scott Garland; Yi Larson; and Andrew Rappaport — to serve until the 2029 annual meeting. The company also reported that an advisory vote on executive compensation was approved and that Ernst & Young LLP was ratified as the company’s independent registered public accounting firm for the year ending December 31, 2026.

Key Details

• Director election votes (For / Withheld / Broker Non-Votes):
  • Sean Bohen, M.D., Ph.D.: 67,474,365 For; 1,165,382 Withheld; 7,496,139 Broker non-votes
  • Scott Garland: 66,184,382 For; 2,455,365 Withheld; 7,496,139 Broker non-votes
  • Yi Larson: 50,371,668 For; 18,268,079 Withheld; 7,496,139 Broker non-votes
  • Andrew Rappaport: 67,276,575 For; 1,363,172 Withheld; 7,496,139 Broker non-votes
• Advisory vote on executive compensation (Say-on-Pay): 67,969,902 For; 653,979 Against; 15,867 Abstain; 7,496,139 Broker non-votes (approved on an advisory basis).
• Ratification of independent auditor: Ernst & Young LLP ratified with 75,811,449 For; 271,918 Against; 52,520 Abstain.
• The Form 8-K was signed by Sean Bohen (President and Chief Financial Officer) and filed June 23, 2026.

Why It Matters
These results confirm board continuity through 2029 and indicate shareholder approval of the company’s executive compensation approach via an advisory vote. Ratification of Ernst & Young LLP as auditor establishes the firm that will handle OLMA’s 2026 audit and related financial reporting. Broker non-votes on some proposals show a portion of shares did not vote on certain matters, which can affect vote tallies for non-routine items.